POSEIDON randomized phase II trial: Tamoxifen (TAM) plus taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2-metastatic breast cancer (MBC)
Accepted version
Repository URI
Repository DOI
Change log
Authors
Description
Keywords
32 Biomedical and Clinical Sciences, 3211 Oncology and Carcinogenesis
Journal Title
ANNALS OF ONCOLOGY
Conference Name
Journal ISSN
0923-7534
1569-8041
1569-8041
Volume Title
32
Publisher
Elsevier BV
Publisher DOI
Rights
Sponsorship
Cancer Research UK (C37096/A16673)